



Oral Health Biotech Company Oral Biolife Announces New CEO and Leadership Updates

Pennsylvania-based biotech company names new executive members to their growing team

BETHLEHEM, PA, UNITED STATES, September 17, 2025 /EINPresswire.com/ -- Oral BioLife (OBL), a regenerative technology company pioneering first-in-class, non-invasive therapies to restore bone and soft tissue, today announced the appointment of Greg Ambra, MS, MBA, as Chief Executive Officer. OBL is advancing a proprietary hydrogel platform that harnesses mechanical stress to generate biological electrical signals, stimulating natural tissue regeneration without the need for surgery or grafting.

With nearly 30 years of global leadership in clinical development, operations, and commercialization, Greg will guide OBL through its next stage of growth across the animal health, dental, and orthopedic markets.

"Greg's appointment comes at a pivotal moment for OBL, as we build on the exciting progress made with our lead asset, Ambrilux Dental Gel™, which had demonstrated compelling results in preclinical studies and is advancing toward FDA approval and commercialization," said Dr. Stella Vnook, Founder and Chairwoman of OBL. "His decades of leadership across pharma and biotech and proven track record in bringing transformative therapies to market make him uniquely suited to accelerate our mission of redefining treatment options for periodontal disease and beyond."

Stepping into the role of Chief Commercialization Officer is Tim Glennon, a seasoned corporate executive with extensive commercial leadership and launch experience across diverse therapeutic areas. Tim brings deep expertise in commercialization, including the launch of more than 15 medical devices and drugs, investor relations, and corporate strategy. He will play a key role in guiding OBL through critical commercialization inflection points, starting with the launch of Ambrilux, its innovative, non-invasive treatment redefining periodontal care.

Mahesh Sambasivam, Ph.D., joins as Head of Manufacturing, bringing over 20 years of experience in the medical device industry. With a career rooted in developing solutions that address unmet patient and caregiver needs, Mahesh brings hands-on clinical insight with a passion for innovation, driving products from concept to market with a focus on real-world impact. His leadership experiences with FDA product approvals and product launches will be key to advancing OBL's pipeline with the same rigor and

efficacy that has defined his prior success.

CEO Greg Ambra said, "I am honored to join Oral BioLife at such a transformative moment in the company's journey. I have great confidence in the strength of our pioneering technology, which holds the potential to meaningfully improve patients' lives. Together with our exceptional team, I look forward to advancing real-world solutions that will make a lasting impact across healthcare."

To learn more about the leadership team at Oral Biolife, visit <https://oralbiolife.com/#leadership>.

About Oral Biolife Inc.

Oral Biolife is an innovative biotechnology company headquartered in Bethlehem, PA that utilizes the unique properties of biotechnology materials to develop breakthrough technologies. Their lead asset, Ambrilux Dental Gel, via its unique non-invasive ability to regenerate bone tissue, represents a potential breakthrough treatment for periodontal disease. For more information, please visit <https://www.oralbiolife.com/> and on LinkedIn at <https://www.linkedin.com/company/oralbiolife-inc/>.

Devyn Barnes
Oral Biolife
+1 407-603-5716
[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/849955253>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.